Study of antiatherogenic effects of simvaglyzin on rabbit’s hypercholesterolemia model
Abstract
In cholesterol-fed rabbits with hypercholesterolemia it was revealed that complex of simvastatin (SV) with glycyrrhizic acid (1–4), simvaglyzin (SVG) had reduced effect on total blood cholesterol (CH) in appropriated equiponderant doses of SV 40, 66,5 and 100 mkg/kg/per day that was equal to such effect of SV 200 mkg/kg/per day. The decrease in total blood CH was 39, 36, 47 и 38 %, respectively, compared to control group after 20 day of drugs administration. Myopathic effect of SVG, evaluated by the blood activity of creatine kinase, was 26, 24 and 29 % lower in stated 3 doses of SVG, respectively, compared to SV dose after 30 day of drugs administration. Also, SVG had antioxidative effect result from reducing of blood lipid peroxidation level on 27–41 % and normalizing endothelium function effect result from reducing of blood levels of von Willebrand factor and endothelin-1 on 26–58 % and 21–29 %, respectively, in appropriated equiponderant doses of SVG 66,6 and 40 mkg/kg/per day that was equal to such effect of SV 200 mkg/kg/per day.
About the Authors
Yu. I. RaginoRussian Federation
SB RAMS
Establishment of the Russian Academy of Medical Sciences Research Institute of Therapy
V. A. Vavilin
Russian Federation
SB RAMS
Establishment of the Russian Academy of Medical Sciences Research Institute of Molecular Biology and Biophysics
N. F. Salakhutdinov
Russian Federation
SB RAS
Institution of the Russian Academy of Sciences Novosibirsk Institute of Organic Chemistry named after N. N. Vorozhtsov
S. I. Makarova
Russian Federation
SB RAMS
Establishment of the Russian Academy of Medical Sciences Research Institute of Molecular Biology and Biophysics
E. M. Stakhneva
Russian Federation
SB RAMS
Establishment of the Russian Academy of Medical Sciences
Research Institute of Therapy
O. G. Safronova
Russian Federation
SB RAMS
Establishment of the Russian Academy of Medical Sciences Research Institute of Molecular Biology and Biophysics
References
1. Anderson K., Castelli W., Levy D. // J. Am. Med. Assoc. 1987. Vol. 257. P. 2176–2180.
2. Оганов Р. Г. / Р. Г. Оганов, Г. Я. Масленникова // Кардиоваск. тер. профил. – 2002. – № 3. – С. 4–8.
3. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. ВНОК // Кардиоваск. тер. профил. – 2007. – № 6. – Приложение. – 28 с.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults // JAMA. 2001. Vol. 285. P. 2486-2497.
5. Puddu P., Puddu G. M., Muscari A. // Acta Cardiol. 2001. Vol. 56. P. 225–231.
6. Bellosta S., Ferri N., Arnaboldi L. et al. // Diabetes Care. 2000. Vol. 23. P. B72–В78.
7. Pereira E., Bertolami M., Faludi A. et al. // Free Radic. Biol. Med. 2004. Vol. 37, N 9. P. 1440–1448.
8. Landmesser U., Bahlmann F., Mueller M. et al. // Circulation. 2005. Vol. 111, N 18. P. 2356–2363.
9. Толстиков Г. А. / Г. А. Толстиков [и др.] // Биоорган. химия. – 1997. – Т. 23, № 9. – С. 691–703.
10. Толстикова Т. Г. [и др.] // Рациональная фармакотерапия в кардиологии. – 2006. – № 1. – С. 55–58.
11. Вавилин В. А. / В. А. Вавилин [и др.] // Биомедицинская химия. – 2008. – Т. 54, вып. 3. – С. 250–265.
12. Толстиков Г. А. Лекарственное средство с гиполипидемическим эффектом «Симваглизин» / Г. А. Толстиков [и др.] – Патент РФ № 2308947 // Бюл. Роспатент. – 2007. – № 30.
13. Hayashi T., Rani P. J. A., Fukatsu A. et al. // Atherosclerosis. 2004. Vol. 176. P. 255–263.
14. Ishida F., Watanabe K., Sato A. et al. // Biochem. Biophys. Acta. 1990. Vol. 1042, N 3. P. 365–373.
15. Kobayashi M., Ishida F., Takahashi T. et al. // Japan J. Pharmacol. 1989. Vol. 49. P. 125–133.
16. Schuh J., Fairclough G., Haschemeyer R. // Proc. Natl. Acad. Sci. USA. 1978. Vol. 75. P. 3173–3179.
17. Mackness B., Mackness M., Arrol S. et al. // Atherosclerosis. 1998. Vol. 139. P. 341–349.
18. Eaton D. L., Klaassen C. D. Principles of Toxicology // Cazarett Doulls Toxicology, McGraw-Hill. N. Y., 2001. P. 11–34.
Review
For citations:
Ragino Yu.I., Vavilin V.A., Salakhutdinov N.F., Makarova S.I., Stakhneva E.M., Safronova O.G. Study of antiatherogenic effects of simvaglyzin on rabbit’s hypercholesterolemia model. Ateroscleroz. 2010;6(1):5-11. (In Russ.)